Latest filing published 22 Jun 2022 for Altimmune, Inc., €137.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Klaus Schafer: trading record in brief
All filings by Klaus Schafer on record concern Altimmune, Inc., in the capacity of board member. Between 4 May 2017 and 20 June 2022, the trades on record add up to 7 filings.
The open-market side counts 1 purchase for €20k alongside 1 sale for €85k. On balance, insiders were net sellers of €66k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 4 option exercises.
On 22 June 2022 came the latest disclosure, an option exercise for €363 in Altimmune, Inc. The most recent open-market purchase was published on 11 December 2020, 2,159 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Klaus Schafer
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 60 shares@ US$2.400.0000% mcap100.0% of flowCommon Stock, par value $0.0001SEC:0001104659-22-073497:0
1 of 1 declaration
